Ikonisys With Evosciences Leasing to Support the Commercial Expansion in Europe and the USA of the Ikoniscope20
12 Mai 2022 - 06:34PM
Business Wire
Regulatory News:
Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO)
(Paris:ALIKO) a company specialized in the early and
accurate detection of cancerous diseases with a unique fully
automated solution for medical analysis laboratories and
Evosciences Leasing, announced today, that they have entered
into a collaboration agreement to support the international market
introduction and further expansion of Ikonisys’ novel and
state-of-the-art platform technology, the Ikoniscope20
system, in the European and US markets.
As a reminder, the ikoniscope20 is the digital fluorescence
microscope system of Ikonisys. It is a fully integrated technology
platform comprising hardware, software and consumables, providing
fully automated slide handling, cell detection and analysis, data
capture, data storage and (remote) review. Ikoniscope20 runs
several FISH applications (technique that identifies and localizes
specific genes in cell suspensions or tissues) routinely used by US
and EU oncology labs, but can also identify and analyze very
promising rare and hard to be detected cells like CTC (Circulating
Tumor Cells) for early cancer detection or treatment
monitoring.
This partnership with Evosciences will support the ramp-up of
Ikonisys’ two-fold worldwide commercialization strategy, on one
side expanding the United States customer base, starting from
converting current customers to active Ikoniscope20 users, and, on
the other, focusing on direct commercialization in Europe (Germany,
France and Italy at first). Ikonisys targets respectively a total
available market of 7,326 laboratories and 3,824 laboratories.
“Based on the successful market development of its former
Ikoniscope Gen1 technology, Ikonisys has launched its novel
miniaturized fully-automated fluorescence microscopy system, the
Ikoniscope20 system, that incorporates latest AI algorithms, as
well as latest advances in optical, mechanical and IT technologies”
said Jurgen Schipper, Chief Commercial Officer of
Ikonisys. “In order to support our international
commercialization plan of the Ikoniscope20 technology, Ikonisys has
partnered with Evosciences Leasing in order to offer tailor-made
sales financing options to all of its customers” continued
Jurgen Schipper.
“We are happy to support Ikonisys and its international
customers by providing flexible financing solutions for the
installation of the Ikoniscope20 technology. Evosciences supports
the procurement of this new and innovative technology with a
financing program tailored to customers’ needs”, stated
Manuela Habeker, VP Evosciences SAS and Managing Director of
Evosciences Leasing GmbH.
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare cells.
Ikonisys has received FDA clearance for several automated
diagnostic applications, which are also marketed in Europe under CE
certification. Through its breakthrough fluorescence microscopy
platform, the company continues to develop a stream of new tests,
including liquid biopsy tests based on Circulating Tumor Cells
(CTC).
For further information, please go to www.ikonisys.com
About Evosciences
Evosciences core competences are individual, flexible, and
tailormade financing solutions in their specialist areas of
analytics, measurement technology and laboratories of all kinds.
Evosciences Group is headquartered in France and present in DACH,
Benelux, France, Spain, Italy, Portugal, UK and the Nordics.
Because the company is independent of banks and leasing companies,
Evosciences is not tied to a particular lender and has access to a
wide range of financial products, when planning and implementing
funding concepts and vendor financing solutions.
For further information, please go to www.evosciences.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220512005916/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Evosciences Manuela Habeker VP Evosciences SAS
mhabeker@evosciences.com
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024